Coreg carvedilol: Marketed to treat mild or moderate heart failure

GSK said data from its COPERNICUS (carvedilol prospective randomized cumulative survival) trial showed a 35% reduction in all-cause mortality compared to placebo (p=0.00013) in advanced heart failure patients already taking ACE inhibitors. The double-blind, placebo-controlled, international study in >2,200 patients also showed a 31% reduction in all-cause mortality or hospitalization for heart failure (p=0.000004), a 27% reduction in all-cause mortality or cardiovascular hospitalization (p=0.00002), and a 24% reduction in all-cause mortality or hospitalization for any reason (p=0.00004). GSK said it will file the data with the FDA to broaden Coreg's indication to include advanced heart failure patients. ...